Market revenue in 2023 | USD 57.1 million |
Market revenue in 2030 | USD 127.7 million |
Growth rate | 12.2% (CAGR from 2023 to 2030) |
Largest segment | Alzheimer's disease |
Fastest growing segment | Alzheimer's Disease |
Historical data | 2018 - 2022 |
Base year | 2023 |
Forecast period | 2024 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Alzheimer's Disease, Parkinson's Disease, Multiple Sclerosis, Autism Spectrum Disorder |
Key market players worldwide | Qiagen NV, Abbott Laboratories, Merck & Co Inc, Johnson & Johnson, Thermo Fisher Scientific Inc, Bio-Rad Laboratories Inc, Sysmex Corp, Merck KGaA, Roche Holding AG, Nimble Therapeutics |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to immunoassay for neurological biomarkers market will help companies and investors design strategic landscapes.
Alzheimer's disease was the largest segment with a revenue share of 36.08% in 2023. Horizon Databook has segmented the UAE immunoassay for neurological biomarkers market based on alzheimer's disease, parkinson's disease, multiple sclerosis, autism spectrum disorder covering the revenue growth of each sub-segment from 2018 to 2030.
The growth of the UAE immunoassays market for neurological biomarkers can be attributed to significant financial resources and adequate government funding. Being a high-income country, the UAE aims at providing universal access to updated & advanced healthcare services to its population by 2021.
Furthermore, the country is witnessing collaborative efforts toward the establishment of a virtual research institute for driving research prospects in the identification of key biomarkers involved in critical neurodegenerative diseases.
In addition, upcoming biomarker conferences to boost R&D efforts in this segment are anticipated to create opportunities for market growth in the country. These include the January 2023 International Conference on Biomarkers of Neurological Disorders (ICBND).
Horizon Databook provides a detailed overview of country-level data and insights on the UAE immunoassay for neurological biomarkers market , including forecasts for subscribers. This country databook contains high-level insights into UAE immunoassay for neurological biomarkers market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account